Pregnancy-Specific Changes in Drug Clearance

Why Clearance Scaling Needs More Than a Gestational Multiplier

Pregnancy can change drug elimination through more than one physiological route. Increased glomerular filtration can raise the renal clearance of a drug eliminated by filtration, while changes in metabolic enzyme activity can alter hepatic intrinsic clearance. These changes do not necessarily produce the same proportional change in total clearance: hepatic blood flow, unbound fraction, and the relative contributions of different pathways all matter.

A reliable PBPK calculation therefore keeps three questions separate: which physiological process changed, which model parameter represents that process, and what concentration basis defines the clearance? This tutorial develops that accounting for renal filtration and hepatic metabolism. It treats binding changes separately from enzyme activity, and shows why clearances must be expressed on the same blood or plasma basis before they are added.

Let \(R_{b:p}=C_b/C_p\) denote the blood-to-plasma concentration ratio for the drug under the conditions being modeled. For the same elimination rate,

The ratio may depend on drug and physiological conditions; it should not silently be assumed to equal one. Pregnancy-specific changes in binding and blood composition require their own parameterization. For the calculations below, any stated fixed binding or blood-to-plasma assumptions are simplifying assumptions, not universal features of pregnancy.

Renal Filtration: Scale the Filtration Process

For a drug eliminated by glomerular filtration, a basic filtration model assumes that only unbound drug in plasma is filtered, that filtration is not limited by another process, and that the filtered drug is not reabsorbed or secreted. If \(GFR\) is the glomerular filtration rate and \(f_{u,p}\) is the unbound fraction in plasma, the filtration clearance referenced to total plasma concentration is

This formula follows because the filtered amount per unit time is \(GFR\) multiplied by the unbound plasma concentration, \(f_{u,p}C_p\). Dividing that elimination rate by \(C_p\) gives \(GFR f_{u,p}\). The units are volume per time, such as mL/min, when \(GFR\) is in mL/min.

To compare this filtration clearance with a clearance referenced to total blood concentration, convert it using the drug’s blood-to-plasma ratio:

If \(GFR\) changes across gestation, scale the filtration component using the gestational \(GFR\) trajectory represented in the maternal PBPK model. Do not apply the \(GFR\) multiplier to metabolic clearance or to a renal pathway that is not governed by filtration. If reabsorption or secretion is important, filtration alone is not the complete renal model.

Hepatic Metabolism: Separate Enzyme Activity From Binding

For hepatic metabolism, a well-stirred liver model relates hepatic blood flow \(Q_H\), the blood unbound fraction \(f_{u,b}\), and intrinsic clearance \(\mathrm{CL}_{\mathrm{int}}\). In this model, \(f_{u,b}\) is specifically the unbound fraction in blood. The model uses total blood concentrations at the liver inlet and outlet, and assumes rapid mixing, a uniform liver concentration, and elimination proportional to unbound concentration through \(\mathrm{CL}_{\mathrm{int}}\). Under these assumptions, hepatic clearance referenced to total blood concentration is

Intrinsic clearance represents the liver’s metabolic capacity with respect to unbound drug under the model definition. A pregnancy-related change in enzyme abundance or activity can be represented as a change in \(\mathrm{CL}_{\mathrm{int}}\). It is not, by itself, a change in \(f_{u,b}\). Conversely, a binding change belongs in the unbound fraction or in a consistent blood/plasma conversion; it must not also be folded into an enzyme-activity multiplier.

If a drug is metabolized by several enzymes, one overall activity multiplier may be inappropriate. A pathway-based representation can scale each baseline intrinsic-clearance contribution separately:

where \(A_k(t)\) is the relative activity factor for enzyme pathway \(k\) at gestational time \(t\), defined relative to the reference condition. This form assumes the pathway contributions can be represented additively in intrinsic clearance and that each activity factor applies to its corresponding contribution. If enzyme-specific contributions or gestational activity factors are unknown, the uncertainty should be made explicit rather than concealed in a single precise-looking multiplier.

The equation also explains why a proportional increase in intrinsic clearance does not always cause the same proportional increase in hepatic clearance. When \(f_{u,b}\mathrm{CL}_{\mathrm{int}}\) is small relative to \(Q_H\), hepatic clearance is sensitive to intrinsic clearance. When it is large relative to \(Q_H\), hepatic clearance approaches \(Q_H\) and is more flow-limited. Gestational changes in hepatic blood flow should therefore be represented separately from enzyme activity, using the appropriate maternal flow trajectory.

Combining Pathways Without Double Counting

For independent elimination pathways acting in parallel, total clearance is the sum of their clearances when all are referenced to the same concentration. A plasma-referenced renal filtration clearance cannot simply be added to a blood-referenced hepatic clearance. Either convert the renal value to blood reference or convert the hepatic value to plasma reference before summing.

Diagnostics, Alternatives, and Limits

Several checks help reveal a faulty pregnancy-scaling calculation:

• Check the concentration reference. Label every clearance as blood- or plasma-referenced. Before summing pathways, confirm that the reference concentration and units match.
• Check the binding definition. Use \(f_{u,p}\) in the stated plasma filtration equation and \(f_{u,b}\) in the blood-based well-stirred liver equation. Do not substitute one for the other without a consistent blood-to-plasma relationship.
• Check the mechanism. A filtration change scales the filtration process; an enzyme activity change scales the relevant intrinsic-clearance contribution. Do not use one physiological multiplier for every pathway.
• Check for double counting. If a changed unbound fraction is already represented in the clearance equation, do not also apply a second multiplier for that same binding effect to intrinsic clearance.
• Check model adequacy. If measured renal elimination includes secretion or reabsorption, filtration-only clearance will not represent the full renal pathway. If the well-stirred assumptions are unsuitable, its hepatic clearance prediction may be biased.

A direct empirical gestational clearance multiplier can be useful when reliable clinical clearance data exist for the relevant drug and population. It summarizes observed net change but does not identify whether filtration, enzyme activity, binding, or another process caused it, and it may not transfer to another drug or gestational period. Mechanistic PBPK scaling instead represents physiological contributors separately, which supports extrapolation and sensitivity analysis but requires more assumptions and input data. Neither approach removes uncertainty: predictions should be checked against available observations and tested for sensitivity to uncertain \(GFR\), enzyme activity, flow, binding, and \(R_{b:p}\).

A further limitation is that a pathway clearance change alone does not determine the full concentration-time profile. Dose, distribution, other elimination routes, and gestational changes in other physiological parameters also matter. The clearance calculations here specify elimination components, not a complete maternal exposure prediction.